Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.
• Treatments: Carteolol; Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Subjects who are considered medically healthy per investigator's judgment

Exclusion Criteria:

• Subjects with ocular conditions as defined by the protocol

• Subjects with intraocular pressure: <10 or ≥22 mmHg